PROJECT

Projects

Environmental & Social Review Summary

Project Number

34313

Company Name

Shandong Weigao Group Medical Polymer Co., Ltd.

Date ESRS Disclosed

Nov 17, 2014

Country

China

Region

East Asia and the Pacific

Last Updated Date

Jun 12, 2021

Environmental Category

B - Limited

Status

Completed

Previous Events

Approved : Dec 18, 2014
Signed : Jan 27, 2015
Invested : Jun 19, 2015

Sector

Pharmaceuticals and Medicine

Industry

Health, Education and Life Sciences

Department

Regional Industry - MAS Asia & Pac

Project Description

Weigao and its subsidiaries (together “the Group”) is the leading manufacturer of single-use medical devices in China. The Group has a wide range of products, which includes: (a) consumables (infusion set, syringes, medical needle, blood bags, pre-filled syringes, blood sampling products, and other consumables); (b) orthopedic materials (such as steel plates and screws); and (c) blood purification consumables (such as dialysis equipment). Weigao is listed on the Hong Kong Stock Exchange.

The blood purification business is based in one of Weigao’s subsidiaries – Weigao Blood. Weigao Blood covers a wide range of blood purification medical devices including hemodialysis machines, high and low flux polysulfone membrane dialyzers and tubing system. In addition to manufacturing, Weigao blood also has a healthcare holding company known as Shandong Weigao Medical Holding Company Limited which runs hemodialysis centers. All the dialysis centers have facilities where patients receive treatment for about 4 hours twice or thrice a week. No patients stay overnight at these centers.

The proposed IFC investment is a debt investment (A loan), proceeds of which will be used towards financing the expansion of Weigao’s blood purification business under its subsidiary, Weigao Blood, through: (i) the expansion of its manufacturing capacity for dialyzer, tubing and related consumables; and (ii) the opening additional company-operated standalone dialysis centers (together, the “Project”).  The expected size of the dialysis centers would be between 10 to 100 treatment beds.

Overview of IFC's Scope of Review

The review of this project builds upon the appraisal and supervision of IFC’s previous debt investment in Shandong Weigao Group Medical Polymer Company Limited (“Weigao” or the “company”) in 2007 and prepaid in 2012. The Environmental & Social Review Summary disclosed for that investment (Project #25099) is available on IFC website at:
ifcext.ifc.org/ifcext/spiwebsite1.nsf/78e3b305216fcdba85257a8b0075079d/465a104f5bfd63cf852576ba000e2941?opendocument

IFC’s review of the proposed investment consisted of appraising technical, environmental, health and safety (EHS) and social information submitted by Weigao, including its safety management system, monitoring guidelines, copies of environment impact assessment and inspection reports, effluent test records, training and inspection records, Human Resource (HR) manual, and grievance mechanism related records. The appraisal included site visits to Weigao’s Blood Purification consumable manufacturing facilities in High Tech Industrial Development Zone (HTIDZ) in Weihai City, in Shandong province of China and a standalone Dialysis center, located in Weihai.

During the appraisal visit, discussions with company’s senior management and facility management staff were held including Chief Financial Officer, Manager of President Office, Head of Corporate Finance, Head of Business Development and Investor Relations, Manager – Human Resources (HR), Vice General Manager of Weihai Weigao Blood Purification Products Company Limited (hereafter referred to as “Weigao Blood”), Manager – Safety, Energy and Resources Department of Weigao Blood, Safety Supervisor of Weigao Blood and Manager – Public Relations and Legal Affairs Department of Weigao.

IFC’s review considered Weigao’s management of its EHS risks and impacts in development and operation of its blood purification equipment manufacturing and dialysis centers, environmental and social management plans for the Project and gaps, if any, between these plans and IFC requirements. Measures included in the management plans and, where necessary, corrective measures intended to close these gaps within a reasonable period of time, are summarized in the paragraphs that follow and in the agreed Environmental and Social Action Plan (ESAP) disclosed in this review summary. Through implementation of these management plans and the ESAP the Project is expected to be designed and operated in accordance with Performance Standards objectives.

E & S Project Categorization and Applicable Standard

Environmental and Social Mitigation Measures

Stakeholder Engagement

Broad Community Support

Environmental & Social Action Plan